Inegy (Simvastatin, Ezetimibe)

Inegy is used to treat lipid disorders and to reduce cardiovascular risk by lowering LDL‑cholesterol.

• Hypercholesterolemia: reduces elevated LDL‑C levels to target goals.
• Mixed dyslipidemia: improves the overall lipid profile, lowering LDL‑C and triglycerides while raising HDL‑C modestly.
• Primary prevention of cardiovascular disease: provides additional LDL‑C reduction in patients who require more intensive therapy to lower the risk of heart attack or stroke.

• Simvastatin inhibits HMG‑CoA reductase, the key enzyme in hepatic cholesterol synthesis, decreasing intracellular cholesterol and up‑regulating LDL receptors. Ezetimibe blocks the NPC1L1 transporter on enterocytes, reducing intestinal absorption of dietary and biliary cholesterol. The combined effect produces an additive reduction in circulating LDL‑cholesterol, enhancing overall lipid‑lowering efficacy compared with either component alone.

The combination of simvastatin and ezetimibe may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache: mild to moderate pain often transient.
• Abdominal discomfort: includes dyspepsia, gas or stomach pain.
• Myalgia: muscle aches without weakness.
• Diarrhea: loose stools occurring intermittently.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown that can lead to renal failure.
• Hepatotoxicity: marked elevation of liver enzymes or hepatitis.
• Severe allergic reactions: rash, angioedema, or anaphylaxis requiring immediate medical attention.

Before initiating Inegy, clinicians should consider several precautionary measures to ensure safe use.

• Liver function monitoring: obtain baseline and periodic liver enzyme tests.
• Muscle symptom assessment: evaluate for unexplained muscle pain, tenderness or weakness.
• Review concomitant medications: avoid strong CYP3A4 inhibitors and other agents that increase statin exposure.
• Contraindication in active liver disease: do not use in patients with unexplained persistent elevations of transaminases.
• Dose adjustment in renal impairment: consider reduced dosing in moderate to severe renal dysfunction.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Inegy can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors): may cause toxic statin levels.
• Gemfibrozil: increases risk of myopathy and rhabdomyolysis.
• High‑dose niacin: potentiates muscle toxicity.
• Cyclosporine: raises simvastatin concentrations, heightening adverse effect risk.
• Cholesterol‑binding resins (e.g., cholestyramine): reduce ezetimibe absorption and efficacy.

Moderate Interactions (Monitor Closely)

• Amiodarone: may modestly increase statin exposure.
• Warfarin: monitor INR as lipid‑lowering therapy can affect anticoagulation.
• Digoxin: slight increase in serum levels may occur.
• Other fibrates (except gemfibrozil): monitor for additive muscle effects.
• Grapefruit juice: can elevate simvastatin levels, requiring caution.